Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19

Florian Tran*, Danielle M.M. Harris, Alena Scharmacher, Hanna Graßhoff, Kristina Sterner, Susanne Schinke, Nadja Käding, Jens Y. Humrich, Otávio Cabral-Marques, Joana P. Bernardes, Neha Mishra, Thomas Bahmer, Jeanette Franzenburg, Bimba F. Hoyer, Andreas Glück, Martina Guggeis, Alexander Ossysek, Andre Küller, Derk Frank, Christoph LangeJan Rupp, Jan Heyckendorf, Karoline I. Gaede, Howard Amital, Philip Rosenstiel, Yehuda Shoenfeld, Gilad Halpert, Avi Z. Rosenberg, Kai Schulze-Forster, Harald Heidecke, Gabriela Riemekasten, Stefan Schreiber

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

8 Scopus citations
Original languageEnglish
JournalERJ Open Research
Volume8
Issue number4
DOIs
StatePublished - 2022
Externally publishedYes

Funding

FundersFunder number
Airway Research Center North
Bundesministerium für Bildung und Forschung
European Commission
COVID-response
Deutsches Zentrum für Lungenforschung
Deutsches Zentrum für Infektionsforschung
Innovative Medicines Initiative
Horizon 2020 Framework Programme733100

    Keywords

    • GPCR autoantibodies
    • Protease-activated receptor 1
    • Severe COVID-19
    • coagulation
    • disease outcome prediction

    Cite this